BioMarin's VOXZOGO Shows Positive Growth Outcomes for Children with Achondroplasia

BioMarin's Groundbreaking Data on VOXZOGO for Children

BioMarin Pharmaceutical Inc. recently unveiled promising new findings regarding their treatment VOXZOGO® (vosoritide) for children diagnosed with achondroplasia. The data, which will be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Baltimore, emphasizes the pivotal role of early treatment in improving various growth-related health metrics, including proportionality and arm span, in young patients with this condition.

VOXZOGO is unparalleled in its approval status as the sole medication authorized for infants with achondroplasia from birth. The extent of its clinical evidence, which encompasses more than 10,000 patient-years, establishes VOXZOGO not just as effective but as a foundational treatment option for managing this genetic disorder.

Early Intervention Yields Maximum Benefits

One of the standout presentations at the ACMG meeting will center around the outcomes from a study investigating children treated with VOXZOGO before they turned two years old. Results indicated substantial, sustained improvements in height and other growth metrics among these children versus untreated peers.

The study assessed changes in the upper-to-lower body segment ratio (ULBR) as a measure of proportionality. The findings indicated that by the first year of treatment, children who received VOXZOGO exhibited a least squares mean difference of -0.33 in ULBR, a figure that significantly improved to -0.53 by year four. This suggests that early recipients of the treatment not only showed broader growth advantages but also maintained stable arm-to-height ratios, highlighting positive developments in arm span.

In terms of height gain, children treated with VOXZOGO illustrated an impressive average height increase of 4.7 cm after four years, with a relevant Z-score improvement further affirming the medicine's long-term efficacy compared to untreated children. These results resonate strongly with the consensus among treating physicians regarding the necessity of early intervention with VOXZOGO to maximize patient outcomes.

Global Insights into Effectiveness

The real-world applications of VOXZOGO are equally compelling, with over 5,000 children receiving the treatment across more than 50 nations. Ongoing studies will showcase real-world data from numerous regions, including Japan, Europe, and the United States. For instance, in Japan, children under two demonstrated an impressive height gain averaging 9.91 cm at the one-year mark, with sustained improvements noted even after two years.

A French study of children over a 36-month period found significant long-term benefits as well; these children displayed an average height gain of 16.7 cm and a notable height Z-score increment. Such international data only strengthens the case for VOXZOGO as a leader in achondroplasia treatment.

A Call for Awareness and Early Treatment Initiation

Michael Hughes, Chair of the Biotech Industry Liaison Committee at Little People of America, expressed optimism regarding these findings, emphasizing the importance of expanding discussions around skeletal health outcomes beyond mere height metrics. As children begin treatment at younger ages, their overall health can significantly improve, making early caregiver and physician awareness critical.

Dr. Greg Friberg of BioMarin also reiterated that enhancing height through VOXZOGO, alongside improvements in body proportionality, underscores the overall benefits of early treatment initiation. As the only approved drug specifically for achondroplasia in infants, VOXZOGO holds immense potential for improving life quality from the earliest stages.

About Achondroplasia and VOXZOGO

For context, achondroplasia is the most prevalent form of skeletal dysplasia associated with disproportionate short stature and is primarily caused by mutations in the FGFR3 gene. The disorder affects the endochondral bone growth process, leading to physical impairments. BioMarin’s VOXZOGO counteracts this by functioning as a positive regulator in the growth pathway, facilitating better bone growth in affected children.

To learn more about ongoing studies and VOXZOGO's application, visit BioMarin’s official clinical trials page. BioMarin remains committed to providing comprehensive resources for caregivers of children with achondroplasia, ensuring access to essential medical support as they navigate these challenges.